RxDoctor Payments Data

Shalini Kamal, MD

Internal Medicine · Baltimore, MDNPI 1316906985

Payments from drug & device makers

$3,246in general payments, 2019–2025

Across 33 payments — averaging $98.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$539
  • Novo Nordisk$297
  • Amgen$125
  • Lilly USA, LLC$101
  • Phadia US Inc.$90

What the payments were for

  • Food & beverage$3,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca19$2,094
AbbVie(2 entities)8$539
Novo Nordisk3$297
Amgen1$125
Lilly USA, LLC1$101
Phadia US Inc.1$90

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,246 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$161,697
Medicare patients
436
Services billed
1,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$66,143
TrulicityDulaglutide31$56,325
JardianceEmpagliflozin36$56,007
EliquisApixaban42$38,935
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$34,927
FarxigaDapagliflozin Propanediol23$27,244
TradjentaLinagliptin24$23,891
Tresiba Flextouch U-200Insulin Degludec23$19,251
MyrbetriqMirabegron15$10,581
Atorvastatin Calcium523$8,219
Rosuvastatin Calcium264$6,866
Pravastatin Sodium242$5,218
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,601
Losartan Potassium267$3,568
Levothyroxine Sodium311$3,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$297$66,14346 claims
Lilly USA, LLCTrulicity$101$56,32531 claims
AstraZenecaFarxiga$2,094$27,24423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →